Data alert

Role of lipid lowering for prevention of cardiovascular events in type 2 diabetes

Cardiovascular (CV) disease is the primary complication and cause of death in people with type 2 diabetes mellitus,1 accounting for nearly two thirds of deaths.2 In 2002, an estimated 6.3% of the US population, or about 18.2 million persons, had diabetes3,4 and data for 2000 indicate that 37.2% of diabetic adults >35 years were diagnosed with CV disease.3,5 The presence of diabetes increases the risk of CV disease 2- to 4-fold in the general population and 5- to 8-fold in women.6

The National Cholesterol Education Program (NCEP), the American Heart Association (AHA), and the American College of Cardiology (ACC) treatment guidelines consider diabetes to be a CV risk factor equivalent to the presence of coronary heart disease (CHD).7,8 Recent AHA guidelines for CV prevention in women also emphasize the importance of diabetes as a CHD risk equivalent.9,10 The updated American Diabetes Association (ADA) guidelines set aggressive goals for treatment as well.11,12

References are listed at the end of the Data Alert.

Recent statin trials: Reduction in primary outcome in patients with diabetes

Download 04VBWG-DA-CARDS.ppt (6 slides - 0.1MB)

Recent statin trials: Reduction in primaryoutcome in patients with diabetes CARDS: Collaborative AtoRvastatin 
Diabetes Study design CARDS: Treatment effects on lipids CARDS: 37% Reduction in primary outcome CARDS: Consistent statin effects on components of primary outcome ACP recommendations for lipid management in patients with diabetes
Data_Alert.pdf (0.6MB)Data_Alert.pdf (0.6MB)


Related at vwbg.org

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section II: Blunting the atherosclerotic process: The case for aggressive lipid management

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

Managing CV Risk in Diabetes: Setting More Aggressive Goals to Meet a Growing Crisis

The evolving diabetes epidemic is raising concern over the adverse long-term effect on cardiovascular (CV) disease.

PROactive: The first prospective clinical outcomes trial of PPAR g agonists

Compared with the general population, persons with diabetes have a twofold greater absolute risk of cardiovascular (CV) disease.
More related